The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | The emergence of novel antibodies, CAR-T and CAR-NK therapies in AML
Fadi Haddad, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the emergence of novel immune-based therapies in acute myeloid leukemia (AML). Novel monoclonal and bispecific antibodies are currently under investigation, and they are expected to induce high response rates in patients with AML. Dr Haddad also comments on the emerging use of CAR-T and CAR-NK therapies, particularly for patients with relapsed/refractory (R/R) AML or with high disease burden. Further investigations that Dr Haddad believes will be beneficial include exploring the efficacy of combined therapy of these novel agents and investigating the impact of immune-based therapies pre- and post-stem cell transplantation (SCT). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
